Prognostic Implications of ras Oncogene Expression in Head and Neck Squamous Cell Carcinoma

  • John Field
Part of the NATO ASI Series book series (NSSA, volume 220)


The ras gene family have been implicated in the development of a range of human cancers (Bos, 1989; Barbacid, 1990; Field and Spandidos, 1990). The ras gene family consists of three functional genes: H-ras, K-ras and N-ras, which encode for very similar proteins with a similar molecular weight of 21,000. Ras p21 proteins are homologous to G proteins, possess GTPase activity and are located on the internal part of the cytoplasmic membrane. A GTPase activating protein has been shown to take part in the hydrolyses of GTP by binding to the effector domain of the ras protein, and thereby takes part in signal transduction (Barbacid, 1987; McCormick, 1989; Schlichting et al., 1990).


Squamous Cell Carcinoma Neck Cancer Oral Cancer Neck Squamous Cell Carcinoma Smokeless Tobacco 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ali, I. U., Lidereau, R., Theillet, C., and Callahan, R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science 238: 185–188 (1987).PubMedCrossRefGoogle Scholar
  2. Azuma, M., Furumoto, N., Kawamata, H., Yoshide, H., Yanagawa, T., Yura, Y., Hayashi, Y., Takegawa, Y. and Sato, M. The relation of ras oncogene product p21 expression to clinico-pathological status and clinical outcome in squamous cell head and neck cancer. The Cancer Journal 1: 375–380 (1987).Google Scholar
  3. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preistinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., White, R. and Vogelstein, B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217–221 (1989).PubMedCrossRefGoogle Scholar
  4. Balmain, A., Ramsden, M., Bowden, G. T. and Smith, J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 307: 658–660 (1984).PubMedCrossRefGoogle Scholar
  5. Barbacid, M. ras genes. An. Rev. Biochem. 56: 779–827 (1987).CrossRefGoogle Scholar
  6. Barbacid, M. ras oncogenes: their role in neoplasia. W. Eur. J. Clin. Inv. 20: 225–235 (1990).CrossRefGoogle Scholar
  7. Bos, J. L. ras oncogenes in human cancer: A review. Cancer Res. 49: 4682–4689 (1989).PubMedGoogle Scholar
  8. Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., Van Boom, J. H., Van der Eb, A. J., Vogelstein, B. Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293–297 (1987).PubMedCrossRefGoogle Scholar
  9. Bremmer, R. and Balmain, A. Genetic changes in skin tumour progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61: 407–417 (1990).CrossRefGoogle Scholar
  10. Brown, K., Buchmann, A. and Balmain, A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc. Natl. Acad. Sci. USA 87: 538–542 (1990).PubMedCrossRefGoogle Scholar
  11. Cancer Research Campaign Factsheet. Oral Cancer, The Lancet 14: 1–5 (1990).Google Scholar
  12. Capon, D. J., Chen, E. Y., Levison, A. D., Seeburg, P. H. and Goeddel, D. V. Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 302: 33–37 (1983).PubMedCrossRefGoogle Scholar
  13. Cattoretti, G., Rilke, F., Andreola, S., D’Amato, L. and Delia, D. p53 expression in breast cancer. Int. J. Cancer 41: 178–183 (1988).PubMedCrossRefGoogle Scholar
  14. Chiba, I., Takahashi, T., Nau, M., D’Amico, D., Curiel, D., Mitsudomi, T., Buchhagen, D., Carbone, D., Piantadosi, S., Koga, H., Reissman, P., Slamon, D., Holmes, E. C. and Minna, J. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5: 1603–1610 (1990).PubMedGoogle Scholar
  15. Crawford, L. V., Pirn, D. C., Gurney, E. G., Goodfellow, P. and Taylor-Papadimitriou, J. Detection of a common feature in several human tumor cell lines — a 53,000 Dalton protein. Proc. Natl. Acad. Sci. USA 78: 41–45 (1981).CrossRefGoogle Scholar
  16. Davis, R. K. Prognostic variables in head and neck cancer. Otolaryng. Clin. N. Amer. 18: 411–419 (1985).Google Scholar
  17. Doll, R. and Peto, R. Mortality in relation to smoking: 20 years observations on male doctors. Br. Med. J. 2: 1525–1536 (1976).PubMedCrossRefGoogle Scholar
  18. Field, J. K. The biology of oncogenes and their role in malignant transformation. In: Risk Markers of Oral Disease 2. Oral Cancer. N. W. Johnson (Ed.), Cambridge University Press, pp. 257–293, 1991.Google Scholar
  19. Field, J. K. and Spandidos, D. Expression of oncogenes in human tumours with special reference to the head and neck region. J. Oral Pathol. 16: 97–107 (1987).PubMedCrossRefGoogle Scholar
  20. Field, J. K. and Spandidos, D. A. Expression of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. A review. Anticancer Res. 10: 1–22 (1990).PubMedGoogle Scholar
  21. Field, J. K., Lamothe, A. and Spandidos, D. A. Clinical relevance of oncogene expression in head and neck tumours. Anticancer Res. 6: 595–600 (1986).PubMedGoogle Scholar
  22. Field, J. K., Spandidos, D. A., Stell, P. M., Vaughan, E. D., Evan, G. I. and Moore, J. P. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 4: 1463–1468 (1989).PubMedGoogle Scholar
  23. Field, J. K., Spandidos, D. A., Yiagnisis, M., Reed, T., Papadimitriou, K. and Stell, P. M. Immunocytochemistry of the C-erb-2 product in head and neck squamous cell carcinoma. In Vivo 4: 88 (1990).Google Scholar
  24. Field, J. K., Yiagnisis, M., Spandidos, D.A., Gosney, J.R., Papadimitriou, K., Vaughan E.D. and Stell, P. M. Low levels of ras p21 oncogene expression correlates with outcome in head and neck squamous cell carcinoma. Eur. J. Surg. Oncol. (in press) (1991a).Google Scholar
  25. Field, J. K., Spandidos, D. A., Malliri, A., Yiagnisis, M., Gosney, J. R. and Stell, P. M. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br. J. Cancer (in press) (1991b).Google Scholar
  26. Forrester, K., Almogvera, C., Han, K., Grizzle, W. E., Perucho, M. Detection of high incidence of Ki-ras oncogenes during human colon tumorigenesis. Nature 327: 298–303 (1987).PubMedCrossRefGoogle Scholar
  27. Friedman, W. H., Rosenblum, B. N., Loewenstein, P., Thornton, A., Katsantonis, G. and Green, M. Oncogenes: their presence and significance in squamous cell cancer of the head and neck. Laryngoscope 95: 313–316 (1985).PubMedGoogle Scholar
  28. Furth, M. E., Davis, I. J., Fleurdelys, B. and Scolnick, E. M. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J. of Virol. 43: 294–304 (1982).Google Scholar
  29. Hoellering, J. and Shuler, C. F. Localization of H-ras mRNA in oral squamous cell carcinomas. J. Oral Pathol. Med. 18: 74–78 (1989).PubMedCrossRefGoogle Scholar
  30. Howell, R. E., Wong, F. S. H., Fenwick, R. C. Activated Kirsten ras oncogene in an oral squamous carcinoma. J. Oral Path. Med. 19: 301–305 (1990).CrossRefGoogle Scholar
  31. Iggo, R., Gatter, K., Bartek, J., Lane, D. and Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675–679 (1990).PubMedCrossRefGoogle Scholar
  32. Johnson, N. W. Oral-facial Neoplasms: Global Epidemiology, Risk Factors and Recommendations for Research. Final Report of Working Group 2 of the Commission on Oral Health, Research and Epidemiology, Federation Dentaire Internationale. London, (1990).Google Scholar
  33. Kaplan, E. L. and Meier, P. Nonparametric estimation from complete observation. J. Amer. Statis. Assoc. 53: 457–481 (1958).CrossRefGoogle Scholar
  34. Krajina, Z., Kucar, Z. and Konic-Carnelutti, V. Epidemiology of laryngeal cancer. Laryngoscope 85: 1155–1161 (1975).PubMedCrossRefGoogle Scholar
  35. Krontiris, T. G., Dimartino, N. A., Colb, M. and Parkinson, D. R. Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature 313: 369–374 (1985).PubMedCrossRefGoogle Scholar
  36. Kumar, R., Saraswati, S. and Barbacid, M. Activation of ras oncogenes preceding the onset of neoplasia. Science 248: 1101–1104 (1990).PubMedCrossRefGoogle Scholar
  37. Kurozumi, S., Harada, Y., Sugimoto, Y. and Sasaki, H. Airway malignancy in poisonous gas workers. Laryngol Otol. 91: 217–223 (1977).Google Scholar
  38. Lane, D. P. and Benchimol, S. p53: oncogene or antioncogene? Genes and Develop 4: 1–8 (1990).CrossRefGoogle Scholar
  39. McCormick, F. ras GTPase activating protein: signal transmitter and signal terminator. Cell 56: 5–8 (1989).PubMedCrossRefGoogle Scholar
  40. McCoy, D. G. and Wynder, E. L. Etiological and preventive implications in alcohol carcinogenesis. Cancer Res. 39: 2844–2850, 1979.PubMedGoogle Scholar
  41. Merrit, W. D., Weissler, M. C., Turk, B. F. and Gilmer, T. M. Oncogene Amplification in Squamous Cell Carcinoma of the Head and Neck. Arch. Otolaryngol. Head Neck Surg. 116: 1394–1398 (1990).CrossRefGoogle Scholar
  42. Myers, E. N. and Suen, J. Y. Cancer of the Head and Neck. 2nd ed., Churchill Livingstone Inc., NY (1989).Google Scholar
  43. Nicholls, P., Edwards, G., Kyle, E. Alcoholics admitted to four hospitals in England. II. General and cause-specific mortaility. Quart. J. Stud. Alc. 35: 841–855, (1974).Google Scholar
  44. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C. and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705–708 (1989).PubMedCrossRefGoogle Scholar
  45. Nordenskjold, M. and Cavenee, W. K. Genetics and the etiology of solid tumors. In: Important Advances in Oncology. DeVita, V. T. Jr., Hellman, S. & Rosenberg, S. A. (eds), p. 83. J. B. Lippincott: Philadelphia (1988).Google Scholar
  46. Oral Cancer, Editorial Lancet 2: 311–312 (1989).Google Scholar
  47. Parada, L. F., Land, H., Weinburgh, R. A., Wolf, D. and Rotter, V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312: 649–654 (1984).PubMedCrossRefGoogle Scholar
  48. Parkin, D. M., Laara, E. and Muir, C. S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer 41: 184–187 (1988).PubMedCrossRefGoogle Scholar
  49. Quintanilla, M., Brown, K., Ramsden, M. and Balmain, A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78–80 (1986).PubMedCrossRefGoogle Scholar
  50. Riou, G., Barrois, M., Sheng, Z. M., Duvillard, P. and Lhomme, C. Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers. Oncogene 3: 329–333 (1988).PubMedGoogle Scholar
  51. Rumsby, G., Carter, R. L. and Gusterson, B. A. Low incidence of ras oncogene activation in human squamous cell carcinomas. Br. J. Cancer 61: 365–368 (1990).PubMedCrossRefGoogle Scholar
  52. Saranath, D., Panchal, R. G., Nair, R., Mehta, A. R. and Deo, M. G. Oncogene amplification in squamous cell carcinoma of the oral cavity. Jpn. J. Cancer Res. 80, 430. (1989).PubMedCrossRefGoogle Scholar
  53. Saranath, D., Chang, S. E., Bhoite, L. T., Panchal, R. G., Kerr, I. B., Mehta, A. R., Johnson, N. W. and Deo, M. G. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br. J. Cancer 63, 573–578 (1991).PubMedCrossRefGoogle Scholar
  54. Schlichting, I., Almo, S. C., Rapp, G., Wilson, K., Petratos, K., Lentfer, Ar., Wittinghofer, A., Kabsch, W., Pai, E., Petsko, G. A. and Goody, R. S. Time-resolved X-ray crystallographic study of the conformational change in Ha-Ras p21 protein on GTP hydrolysis. Nature 345: 309–315 (1990).PubMedCrossRefGoogle Scholar
  55. Schmidt, W. and de Lint, J. Estimating the prevalence of alcoholism from alochol consumption and mortality data. Quart. J. Stud. Alc. 31: 957–964 (1970).Google Scholar
  56. Schmidt, W. and Popham, R. E. The role of drinking and smoking in mortality from cancer and other causes in male alcoholics. Cancer 47: 1030–1041 (1981).CrossRefGoogle Scholar
  57. Sheng, Z. M., Barrois, M., Klijanienko, J., Micheau, C., Richard, J. M. and Riou, G. Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br. J. Cancer 62: 398–404 (1990).PubMedCrossRefGoogle Scholar
  58. Silverman, S. and Griffith, M. Smoking characteristics of patients with oral carcinoma and risk for second oral primary carcinoma. J Am Dent Assoc. 85: 637–642 (1972).PubMedGoogle Scholar
  59. Spandidos, D. A., Lamothe, A. and Field, J. K. Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Res. 5: 221–224 (1985).PubMedGoogle Scholar
  60. Stell, P. M. Smoking and laryngeal cancer. Lancet 1: 617–618 (1972).PubMedCrossRefGoogle Scholar
  61. Stell, P. M. Prognostic factors in laryngeal carcinoma. Clin. Otol. 13: 399–409 (1988).CrossRefGoogle Scholar
  62. Suarez, H. G., Du Villard, J. A., Caillou, B., Schlumberger, M., Tubiana, C., Parmentier, C., Monier, R. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 2: 403–406 (1988).PubMedGoogle Scholar
  63. Takahashi, T., D’Amico, D., Chiba, I., Buchhaben, D. and Minna, J. Identification of intronic mutations as an alternative mechanism for p53 inactivation in lung cancer. J. Clinical Invest. 86: 363–369 (1989).CrossRefGoogle Scholar
  64. Tanaka, T., Slamon, D. J., Shimoda, C. W., Kawaguchi, Y., Tanaka, Y. and Ida, N. Expression of Ha-ras oncogene in human neuroblastomas and the significant correlation with patient prognosis. Cancer Res. 48: 1030–1034 (1988).PubMedGoogle Scholar
  65. Tsuji, T., Sasaki, K., Hiraoka, F. and Shinozaki, F. The immunohistochemical detection of ras p21 and its correlation with differentiation in oral cancers. Journal of Tumour Marker Oncology 4: 415–419 (1989).Google Scholar
  66. Union Internationale Contre le Cancer. TNM Classification of malignant tumours. Eds. P. Hermanek and L. Fobin. Springer Verlag, Heidelberg (1987).Google Scholar
  67. Wynder, E.L. and Stellman, S.D. Comparative epidemiology of tobacco-related cancers. Cancer Res. 37: 4608–4622 (1977).PubMedGoogle Scholar
  68. Wynder, E. L., Bross, I. J., Day, E. Epidemiological approach to the etiology of cancer of the larynx. JAMA 160: 1384–1389 (1956).CrossRefGoogle Scholar
  69. Zarbl, H., Sukumar, S., Arthur, A. V., Martin-Zanca, D and Barbacid, M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315: 382–385 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • John Field
    • 1
  1. 1.Department of Clinical Dental Sciences School of DentistryUniversity of LiverpoolLiverpoolUK

Personalised recommendations